Why do patients respond so differently to the same treatment? Five years of the Turing Roche partnership
A UK academic-industry biomedical AI partnership closure with no immediate Australian public sector policy parallel.
Key points
- The five-year Alan Turing Institute and Roche partnership concludes, focused on patient treatment response research.
- Research centred on biomedical/clinical AI applications - not public sector governance or Australian policy.
- No direct relevance to APS AI governance or Australian federal agency operations.
View original source
Copied.
"Why do patients respond so differently to the same treatment? Five years of the Turing Roche partnership"
Source: Alan Turing Institute – Blog
Published: 14 July 2026
URL: https://www.turing.ac.uk/blog/why-do-patients-respond-so-differently-same-treatment-five-years-turing-roche-partnership
The Alan Turing Institute marks the conclusion of its five-year research partnership with pharmaceutical company Roche, which focused on understanding why patients respond differently to the same medical treatments. The blog post reflects on the partnership's research outputs and the research community it developed. The work sits within biomedical and clinical AI applications rather than AI governance, public sector practice, or Australian policy contexts.
Retrieved from SIMS, 18 July 2026.